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Progression and Regression of Coronary
Atherosclerosis Occur within the Same Patient
During Placebo Treatment and During Lipid-Lowering
Therapy with Pravastatin
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Conclusion: significant progression and regression of CA within the same
patient occurred in 41 (13%) PRAY-patients and in 27 (9%) PLAC-patients.
Thus, although pravastatin slows mean progression of CA, progression and
regression of CA within the same patient still occurs in a considerable num-
ber of patients during lipid lowering therapy.
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endpoints were OCA assessments of 1. change in Mean Segment Diameter
(MSD) averaged per patient and 2. change in Minimum Obstruction Diameter
(MOD) averaged per patient.
Results: 77B patients (BB%) of the patients had an evaluable final an-
giogram. Mean Segment Diameter decreased with 0.10 mm in the placebo
group versus 0.06 mm in the pravastatin group (p = 0.019): the mean differ-
ence between treatment groups was 0.04 mm with 95% confidence interval
(ei) of 0.01-0.07 mm. The median Minimum Obstruction Diameter decreased
with 0.09 mm in the placebo group versus 0.03 mm in the pravastatin group
(p = 0.001): the difference of the medians between the treatment groups
was 0.06 mm with ei of 0.02-o.0B mm. At the end of the follow-up period
89% (ci B6-92%) of the pravastatin patients and 81 % (ei 77-85%) of the
placebo patients were without new cardiovascular events (p = 0.002).
Conclusions: in symptomatic men with normal or moderately raised serum
cholesterol, pravastatin slows progression of coronary atherosclerosis and
reduces the number of cardiovascular events.
J. Wouter Jukema. Ad J. van Boven, Johan H.C. Reiber. Aeilko H. Zwinderman.
Albert VG. Bruschke. REGRESS study group Interuniversity Cardiology Institute,
Utrecht The Netherlands
REGRESS (Regression Growth Evaluation Statin Study) is a placebo con-
trolled multicenter study to asses the effect of 2-yr treatment with Pravas-
tatin (PRAV) on progression and regression of angiographically documented
coronary atherosclerosis (CA) in patients with a serum cholesterol between
4--B mmol~ (155-310 mg/dl). Analyses of the coronary arteriograms were
performed by quantitative computer analysis. The primary endpoints of the
study, change in Mean Segment Diameter and Minimum Obstruction Diam-
eter (MOD) averaged per patient, showed significant retardation of mean
progression of CA in the PRAY-group as compared to the placebo (PLACj-
group. However, these mean changes per treatment group are hardly infor-
mative about individual CA-behavior. Therefore we determined for all 641
patients included in the primary MOD-analysis: 1. a mean progression score
(MPS)-cumulative value of all >0.4 mm progressing obstructions divided by
the number of contributing obstructions-, and 2. a mean regression score
(MRSj-cumulative value of all >0.4 mm regressing obstructions divided by
the number of contributing obstructions. Obstructions changing :::,:0.4 mm
were considered stable and do not contribute to the scores. Thus, each pa-
tient is characterized by a MPS and a MRS. An overview of the patient MPS
and MRS is presented in the figure below.
1769-31 Lipid Intervention and Progression of Coronary
Atherosclerosis
U.F.E. Rensing, H.P. Bestehorn, J. Petersen, K. Peters, P. Betz. K. Braunagel.
M. Spinder. L. Samek. H. Roskamm. L. Benesch, K. Schemeitat, G. Blumchen,
J. Claus, P. Mathes, L. Kappenberger 1, H. Wieland, J.F. Boeker, A. Neiss.
Herz-Zentrum 0-79188 Krozingen and 4 other cardiology centers in Germany:
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The Coronary Intervention Study, CIS. is a multicentre, randomized, double-
blind. placebo-controlled study to investigate the effects of lipid-modifying
therapy on progression in 254 men with documented coronary artery dis-
ease (CAD) and hypercholesterolemia. Entry criteria were the presence of
at least 3 coronary stenoses of :::25% and a mean serum total cholesterol
1st angio 2nd angio 6-
(mm) Imm) (mm)
1.15±0.28 0.91 ±0.52* 0.24±0.47
1.71 ±0.50 1.61 ± 0.53* 0.10±0.31!
1.13±0.280.79±0.54* 0.34±0.51
1.18±027 113±0.38 005±0.301
1st angio 2nd anglo /'>.
(%) (%) (%)
IRS 66.2±6.6 72.8± 16.9* 6.6± 15.8
non~RS 44.6 ± 14.5 48.0 ± 15.8* 3.4 ± 12.2!
Com IRS 66.9±7.1 76.5± 16.3* 9.6± 17.2
Smo IRS 64.8 ± 5.3 65.5 ± 12.1 0.71 ± 10.61
Clinical syndrome FP(%) LP(%) P
Stable/asymptomatic (10) 9(90) 1 (10)
] NS] ]<001New or Crescendo (16) 9(56) 7 (44)
Rest Angina (21) 4(19) 17 (81) ] NSPost-MI (13) 2(15) 11 (85)
Albert VG. Bruschke. J. Wouter Jukema. Ad J. van Boven. Johan H.C. Reiber.
Egbert T. Bal. Aeilko H. Zwinderman. Kong I. Lie. REGRESS study group
Interuniversity Cardiology Institute, Utrecht The Netherlands
REGRESS is a double blind, placebo controlled multicenter study to assess
the effect of 2 year treatment with pravastatin 40 mg once daily on pro- and
regression of angiographically documented coronary artery disease in BB5
patients with a serum cholesterol between 4--8 mmol~ (155 and 310 mg/dl).
The REGRESS study comprises three blocks of patients: a percutaneous
coronary angioplasty, a coronary artery bypass grafting and a medical man-
agement group. Analysis of baseline and follow-up coronary arteriograms
was performed visually and by quantitative computer analysis (OCA). Primary
The Influence of Pravastatin on Progression and
Regression of Coronary Atherosclerosis in Men with
Normal or Mildly Raised Serum Cholesterol. Results
of the Regression Growth Evaluation Statin Study
(REGRESS)
Coronary thrombus on histologic analysis was present in 23/36 164%) of
LP vs. in 5/24 (21 %) of FP (p < 0.01). Coronary thrombus was present in
BB% and B2% of LP in rest angina and post MI respectively. Inflammatory
cells were noted in 12 LP and 2 FP (p = 0.02) - in 38% of both rest angina
and post MI specimens. Conclusions: Lipid rich plaque are very common
in rest angina and post MI. moderately common in crescendo or new on-
set and rare in stable angina. LP are usually associated with thrombus and
inflammation particularly in rest angina and post MI pts. These DCA tissue
analyses confirm and expanded on prior autopsy studies in acute syndromes
and support the pathogenetic link between unstable rest angina and acute
MI.
Despite clinical stabilization. IRS are unstable and at high risk for rapid pro-
gression to total occlusion, which is usually assoeiated with coronary events.
Data are mean ± SD. *p < 0.01 vs. 1st angio by paired t-test; !p < 0.05 vs. IRS. and I p <
0.01 vs. Com IRS by unpaired t-test. Com = complex. Smo = smooth
Samin K. Sharma. Billie Fyfe. Ram Bongu. Jeremy Asnes. Jonathan D. Marmur.
Thomas Cocke. Orlandino D. Almeida. John A. Ambrose. Mount Sinai Hospital. New
York. N.Y.
Several autopsy studies indicate that disrupted atherosclerotic plaques par-
ticularly those rich in lipid with associated thrombus. are the cause of acute
MI. Other plaques without disruption are fibrocellular without lipid. Although
unstable rest angina (UA) shares a common pathogenesis to acute MI. there
are little pathological data on plaque composition in UA. Directional Coronary
Atherectomy (DCA) provides the opportunity to study plaque composition in
UA. Methods: We prospectively analyzed the DCA tissue specimens of 60
pts with de novo culprit lesions for fibrocellular and lipid constituents by
hematoxylin & eosin and oil red 0 stains. A fibrous plaque (FP) was defined
as one which had predominantly fibrous and sclerotic tissue with no or min-
imallipid (0 or 1+ on scale of 3). A lipid plaque (LP) was defined as one with
moderate or high lipid (2 or 3+) content. The presence of inflammatory cells
and thrombus were also noted. Histopathology was analyzed independent
of clinical presentation.
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